Athanor Capital’s Relmada Therapeutics RLMD Stock Holding History

Athanor Capital’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-6,913	Closed	-$309K	–	648
2020 Q2	$309K	Buy	+6,913	New	+$292K	0.02%	409

Other funds holding RLMD

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Athanor Capital's RLMD Position: Q3 2020 in Review

Athanor Capital sold out of Relmada Therapeutics (RLMD) in Q3 2020, closing a stake of 6,913 shares — an estimated $309K sold.

Athanor Capital first reported a position in RLMD in Q2 2020 and held it in 1 quarter. The position peaked at $309K in Q2 2020. 72 funds tracked by Wall St. Rank hold RLMD as of Q3 2020.

Athanor Capital reported no remaining Relmada Therapeutics position as of Q3 2020 after selling out during the quarter.
Athanor Capital sold 6,913 Relmada Therapeutics shares in Q3 2020, an estimated $309K.
Athanor Capital first reported a position in Relmada Therapeutics in Q2 2020 and held it in 1 quarter.
Athanor Capital's Relmada Therapeutics position peaked at $309K in Q2 2020.
72 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2020.

Based on Athanor Capital's 13F filing for Q3 2020, filed 16 Nov 2020.